CCEL (Cryo-Cell International) Gross Profit Margin

Corporate emblem and logo of Cryo-Cell International (CCEL)

Quarterly gross margin confirms the stability of biobanking revenues, which correlates with profit forecasts for Cryo-Cell International (CCEL). Growth is based on leadership in umbilical cord blood storage for families and an impeccable thirty-year track record of tissue preservation. 76.20 shows the current metric value, capturing the efficiency of cost-of-services management in the current period.

CCEL: Cryo-Cell Gross Profitability 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for Cryo-Cell International (CCEL)

- price and consensus price forecast:
Basic company analysis:Cryo-Cell International, Inc.
Manufactured products of Cryo-Cell International Inc

Gross margin measures the efficiency of direct production, determining the profit share of each unit of revenue after deducting variable service delivery costs. By analyzing gross margin growth, an investor assesses the ability of Cryo-Cell International (CCEL) to optimize biomaterial storage and capitalize on the transition to high-margin cell therapy, which is critical for the monetization of accumulated assets by 2026.